EVPL and chronic myelogenous leukemia, BCR-ABL1 positive: Previously, we have developed a p210-breakpoint derived penta-peptide vaccine for controlling minimal residual disease in Chronic Myeloid Leukemia (CML) patients treated with imatinib [7].